RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $34 to $35.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.